Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
33 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
SymBio Pharmaceuticals Limited - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'SymBio Pharmaceuticals Limited - Product Pipeline Review - 2014', provides an overview of the SymBio Pharmaceuticals Limited's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of SymBio Pharmaceuticals Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of SymBio Pharmaceuticals Limited including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of SymBio Pharmaceuticals Limited's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the SymBio Pharmaceuticals Limited's pipeline products Reasons to buy - Evaluate SymBio Pharmaceuticals Limited's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of SymBio Pharmaceuticals Limited in its therapy areas of focus - Identify new drug targets and therapeutic classes in the SymBio Pharmaceuticals Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of SymBio Pharmaceuticals Limited and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of SymBio Pharmaceuticals Limited - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of SymBio Pharmaceuticals Limited and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 SymBio Pharmaceuticals Limited Snapshot 4 SymBio Pharmaceuticals Limited Overview 4 Key Information 4 Key Facts 4 SymBio Pharmaceuticals Limited - Research and Development Overview 5 Key Therapeutic Areas 5 SymBio Pharmaceuticals Limited - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Pipeline Products - Partnered Products 9 Partnered Products/Combination Treatment Modalities 10 SymBio Pharmaceuticals Limited - Pipeline Products Glance 11 SymBio Pharmaceuticals Limited - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Phase I Products/Combination Treatment Modalities 12 SymBio Pharmaceuticals Limited - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 SymBio Pharmaceuticals Limited - Drug Profiles 14 bendamustine hydrochloride 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 rigosertib sodium 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 SyB-0702 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 SymBio Pharmaceuticals Limited - Pipeline Analysis 21 SymBio Pharmaceuticals Limited - Pipeline Products by Target 21 SymBio Pharmaceuticals Limited - Pipeline Products by Route of Administration 22 SymBio Pharmaceuticals Limited - Pipeline Products by Molecule Type 23 SymBio Pharmaceuticals Limited - Pipeline Products by Mechanism of Action 24 SymBio Pharmaceuticals Limited - Recent Pipeline Updates 25 SymBio Pharmaceuticals Limited - Discontinued Pipeline Products 30 Discontinued Pipeline Product Profiles 30 forigerimod 30 SymBio Pharmaceuticals Limited - Locations And Subsidiaries 31 Head Office 31 Appendix 32 Methodology 32 Coverage 32 Secondary Research 32 Primary Research 32 Expert Panel Validation 32 Contact Us 33 Disclaimer 33
List of Tables SymBio Pharmaceuticals Limited, Key Information 4 SymBio Pharmaceuticals Limited, Key Facts 4 SymBio Pharmaceuticals Limited - Pipeline by Indication, 2014 6 SymBio Pharmaceuticals Limited - Pipeline by Stage of Development, 2014 7 SymBio Pharmaceuticals Limited - Monotherapy Products in Pipeline, 2014 8 SymBio Pharmaceuticals Limited - Partnered Products in Pipeline, 2014 9 SymBio Pharmaceuticals Limited - Partnered Products/ Combination Treatment Modalities, 2014 10 SymBio Pharmaceuticals Limited - Phase II, 2014 11 SymBio Pharmaceuticals Limited - Phase I, 2014 12 SymBio Pharmaceuticals Limited - Preclinical, 2014 13 SymBio Pharmaceuticals Limited - Pipeline by Target, 2014 21 SymBio Pharmaceuticals Limited - Pipeline by Route of Administration, 2014 22 SymBio Pharmaceuticals Limited - Pipeline by Molecule Type, 2014 23 SymBio Pharmaceuticals Limited - Pipeline Products by Mechanism of Action, 2014 24 SymBio Pharmaceuticals Limited - Recent Pipeline Updates, 2014 25 SymBio Pharmaceuticals Limited - Discontinued Pipeline Products, 2014 30
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.